These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9009252)

  • 1. Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice.
    Singhal S; Vourka-Karussis U; Mehta J; Slavin S; Weiss L
    Leuk Res; 1996; 20(11-12):941-6. PubMed ID: 9009252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice.
    Weiss L; Reich S; Slavin S
    Bone Marrow Transplant; 1996 May; 17(5):789-92. PubMed ID: 8733699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
    Palathumpat V; Dejbakhsh-Jones S; Strober S
    Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation.
    Salam A; Waer M
    Transplantation; 1996 Mar; 61(5):826-30. PubMed ID: 8607190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells.
    Glass B; Uharek L; Zeis M; Loeffler H; Mueller-Ruchholtz W; Gassmann W
    Br J Haematol; 1996 May; 93(2):412-20. PubMed ID: 8639441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD; McCabe C; Hanke CA; Truitt RL
    J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation.
    Charak BS; Agah R; Mazumder A
    Blood; 1992 Jul; 80(1):179-84. PubMed ID: 1611084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.